Taiho Pharmaceutical Co. | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

22,609 results for “Taiho Pharmaceutical Co.”

Taiho Pharmaceutical Challenges USPTO Over $1 Billion LYTGOBI Patent Extension Denial

Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 REZILIENT3 Trial for First-Line EGFR Exon 20 Insertion NSCLC

Cullinan Oncology and Taiho Pharmaceutical Forge $275M Strategic Collaboration for EGFR Inhibitor CLN-081/TAS6417

Zipalertinib Plus Chemotherapy Cuts Progression Risk 50% in First-Line EGFR Exon 20 Insertion NSCLC

Taiho Pharmaceutical Exercises Option for Casdatifan HIF-2α Inhibitor in Asia-Pacific Territories

Chugai Pharmaceutical Licenses Araris' AraLinQ Technology for Next-Generation ADC Development

Zipalertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion Mutations

Taiho Pharmaceutical to Acquire Swiss ADC Pioneer Araris Biotech for Up to $1.14 Billion

Merck Launches Phase 3 KANDLELIT-007 Trial for Calderasib-KEYTRUDA QLEX Combination in KRAS G12C-Mutant Lung Cancer

Merck Launches Phase 3 Trial of MK-1084 Plus Pembrolizumab for KRAS G12C-Mutated NSCLC

Page 1 of 1386